LY2452473

Research use only, not for human use.

LY2452473 (TT 701;OPK 88004) is an orally bioavailable selective androgen receptor modulator (SARM) being developed for the treatment of disorders related to hypogonadism.

LY2452473 (TT 701;OPK 88004) is an orally bioavailable selective androgen receptor modulator (SARM) being developed for the treatment of disorders related to hypogonadism; has the potential advantage of eliciting androgen receptor specificity and tissue selectivity to produce the beneficial effects of testosterone on bone, muscle, and improvements in erectile function over a PDE5i alone, with minimal steroid-related adverse effects.Prostate Cancer Phase 2 Clinical.

——

LY2452473 is a selective androgen receptor modulator being developed for the treatment of disorders related to hypogonadism. LY2452473 is absorbed rapidly (time to reach maximum plasma concentration for both LY2452473 and total radioactivity is 2-3 h) and cleared slowly (plasma terminal t1/2 of 27 h for LY2452473 and 51 h for the total radioactivity).

TT 701 | OPK 88004

Endocrinology/Hormones

Androgen Receptor (AR)

Androgen Receptor (AR)

Cancer

Prostate Cancer

1029692-15-6

374.444

C22H22N4O2

>98% (HPLC)

DMSO : 62.5 mg/mL 166.92 mM

O=C(OC(C)C)N[C@H](C1)CC2=C1N(CC3=NC=CC=C3)C4=C2C=C(C#N)C=C4

Isopropyl N-[(2S)-7-cyano-4-(2-pyridylmethyl)-2,3-dihydro-1H-cyclopenta[b]indol-2-yl]carbamate

(-20℃)

With Ice Pack

≥ 2 years